The annual general meeting in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) was held on 24 April 2024 in Stockholm whereby the shareholders primarily resolved on the following matters.
Adoption of the income statement and the balance sheet: allocation of result
The annual general meeting adopted the income statement and balance sheet for the Company in accordance with submitted accounting documents. The annual general meeting further resolved to allocate the Company’s result in accordance with the board of directors’ proposal, i.e. that the Company’s result be carried forward in its entirety. The resolution entails that no dividend is paid for the financial year 2023.
Discharge from liability
The annual general meeting resolved to discharge the board members and the CEO from liability for the financial year 2023.
Resolution on remuneration to the board and auditor
The annual general meeting resolved, in accordance with the nomination committee’s proposal, on board remuneration with the following allocation: SEK 200,000 to the chairperson and SEK 100,000 to each of the other board members.
Further, the annual general meeting resolved, in accordance with the nomination committee’s proposal, that the auditor shall be paid against approved invoice.
Election of board members and auditor
The annual general meeting resolved to re-elect Hans Larsson, Carl Bjartmar, Marianne Jensen Waern, Bo Nilsson, Bertil Villard and Martin Åmark as members of the board of directors. Hans Larsson was re-elected as chairperson.
The annual general meeting resolved to re-elect KPMG AB as the Company’s auditor, with Per Hammar as the auditor in charge.
Resolution regarding a nomination committee and guidelines for the work of the nomination committee
The annual general meeting resolved to re-elect Kristina Nilsson Ekdahl, Johan Thorell, Pär Josefsson, Marianne Jensen Waern and Hans Larsson as members of the nomination committee.
Further, the nomination committee’s proposal to adopt instructions for the work of the nomination committee was approved by the annual general meeting.
Resolution regarding authorisation for the board of directors to issue new shares, warrants and/or convertible instruments
The annual general meeting resolved, in accordance with the board of directors’ proposal, to authorise the board, for the period up to the next annual general meeting to resolve, whether on one or several occasions, to increase the Company’s share capital by way of issue of shares, warrants and/or convertible instruments. The board of directors shall be authorised to adopt resolutions on an issue of shares, warrants and/or convertible instruments with deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off.
The board of directors shall however not be authorised to adopt resolutions that result in an increase of the share capital of the Company of more than sixty (60) percent in relation to the share capital of the Company at the time of the authorisation first being utilised.
An issue in accordance with the authorisation shall be on market conditions. The board of directors shall be authorised to resolve on the terms and conditions regarding issues under the authorisation and what persons shall be entitled to subscribe for the shares, warrants and/or convertible instruments. The Company shall be able to issue shares, warrants and/or convertible instruments in order to raise capital, tie strategically important shareholders to the Company or to carry out acquisitions or strategic cooperations.
Majority requirements etc.
All resolutions at the annual general meeting were adopted unanimously.
————————————
iCoat Medical AB (publ)
The board of directors
For more information, please contact:
Peder Waern, CEO, iCoat Medical AB (publ)
E-mail: peder.waern@icoatmedical.com